
|Videos|August 11, 2014
Dr. Brufsky Discusses Future Research into Bisphosphonates
Author(s)Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.
Advertisement
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.
The cancer cell itself is incredibly complex, Brufsky says. Much work has been done to understand cancer cells with next-generation sequencing and RNA-based assays.
Drugs like bisphosphonates and denosumab affect the host greatly. Research needs to be conducted focused on the genomics of the host and the factors that allow metastatic disease to come about from the host’s perspective.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
2
FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma
3
ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention
4
Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer
5




















































